A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.
VTAs can be small-molecule or ligand-based.
Small-molecule VTAs include: microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503 vadimezan (ASA404)
Clinical trials Phase II : ZD6126, CA4P, plinabulin (NPI-2358)
Phase III : DMXAA (ASA404).
References